Clinical Trial Update: A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL) [Phase 1]

View source ↗

Summary

A Phase 1 study of CC-122 in Japanese patients with advanced solid tumors and Non-Hodgkin lymphoma was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma
• Solid Tumors

Drugs mentioned

• CC-122

Snippet

Sponsor: Celgene | Conditions: Lymphoma, Non-Hodgkin | Phase 1 | Status: TERMINATED | Results posted: 2024-09-23